In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008

Diagnostic Microbiology and Infectious Disease

Volumn 68, Issue 1, 2010, Pages 73-79

  Wang, Yun F Wayne ^a,b   Dowzicky, Michael J ^c  

^a GRADY MEMORIAL HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

Acinetobacter; Bacteremia; Resistance; Surveillance; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER JUNII; ACINETOBACTER LWOFFII; ADOLESCENT; ADULT; AFRICA; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA;

EID: 77955822367     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.04.002     Document Type: Article

References (33)

1. Abbo A., Navon-Venezia S., Hammer-Muntz O., Krichali T., Siegman-Igra Y., Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg. Infect. Dis. 2005, 11:22-29.
2. Aquirre-Avalos G., Mijangos-Méndez J.C., Zavala-Silva M.L., Coronado-Magaña H., Amaya-Tapia G. Bacteremia caused by Acinetobacter baumannii among patients in critical care. Gac. Med. Mex. 2009, 145:21-25.
3. Bantar C., Curcio D., Fernandez Canigia L., Garciá P., Guzman Blanco M., Leal A.L. Comparative in vitro activity of tigecycline against bacteria recovered from clinical specimens in Latin America. J. Chemother. 2009, 21:144-152. Latin American Tigecycline Surveillance Group.
4. Casal M., Rodríguez F., Johnson B., Garduno E., Tubau F., de Lejarazu O., Tenorio A., Giménez M.J., Bartolomé R., Garcia-Rey C., Aguilar L., García-Escribano N. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J. Antimicrob. Chemother. 2009, 64:69-72.
5. Clinical and Laboratory Standards Institute (CLSI) Performance standard for antimicrobial susceptibility testing (M100-S16) 2006, CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute (CLSI) Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; approved standard-sixth edition, M11-A7 2008, Wayne, PA.
7. Conte J.E., Golden J.A., Kelly M.G., Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 2005, 25:523-529.
8. Cunha B.A. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J. Clin. Microbiol. 2009, 47:1613.
9. Eser O.K., Ergin A., Tunckanat F., Hascelik G. In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp. New Microbiol. 2008, 31:535-542.
10. Fernández Canigia L., Kaufman S., Lanata L., Vay C., Giovanakis M., Bantar C. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Chemotherapy 2009, 55:20-27. Argentinean Tigecycline Surveillance Group.
11. Fernández-Mazarrasa C., Mazarrasa O., Calvo J., del Arco A., Martínez-Martínez L. High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest. J. Clin. Microbiol. 2009, 47:827-829.
12. Gordon N.C., Wareham D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother. 2009, 63:775-780.
13. Hope R., Parsons T., Mushtaq S., James D., Livermore D.M. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method. J. Antimicrob. Chemother. 2007, 60:770-774.
14. Jones M.E., Draghi D.C., Thornsberry C., Karlowsky J.A., Sahm D.F., Wenzel R.P. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American surveillance study (2000-2002). Ann. Clin. Microbiol. Antimicrob. 2004, 3:14. available online at. http://www.ann-clinmicrob.com/content/3/1/14.
15. Jones R.N., Ferraro M.J., Reller L.B., Schreckenberger P.C., Swenson J.M., Sader H.S. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J. Clin. Microbiol. 2007, 45:227-230.
16. Karageorgoloulos D.E., Kelesidis T., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J. Antimicrob. Chemother. 2008, 62:45-55.
17. Liao C.H., Kung H.C., Hsu G.J., Lu P.L., Liu Y.C., Chen C.M., Lee C.M., Sun W., Jang T.N., Chiang P.C., Cheng Y.J., Lin H.C., Shi Z.Y., Wang L.S., Chuang Y.C., Tsao S.M., Lu C.T., Liu J.W., Huang C.H., Hsueh P.R. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. Int. J. Antimicrob. Agents 2008, 32:S192-S196.
18. Liu J.W., Wang L.S., Cheng Y.J., Hsu G.J., Lu P.L., Liu Y.C., Chen C.M., Lee C.M., Sun W., Jang T.N., Chiang P.C., Chuang Y.C., Lin H.C., Shi Z.Y., Kung H.C., Huang C.H., Tsao S.M., Lu C.T., Liao C.H., Hsueh P.R. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan. Int. J. Antimicrob. Agents 2008, 32:S188-S191.
19. Livermore D.M. Tigecycline: what is it, and where should it be used?. J. Antimicrob. Chemother. 2005, 56:611-614.
20. Meagher A.K., Ambrose P.G., Grasela T.H., Ellis-Grosse E.J. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn. Microbiol. Infect. Dis. 2005, 52:165-171.
21. Muralidharan G., Micalizzi M., Speth J., Raible D., Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 2005, 49:220-229.
22. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, document M7-A6 2003, National Committee for Clinical Laboratory Standards, Wayne, PA.
23. Navon-Venezia S., Leavitt A., Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 2007, 59:772-774.
24. Paul M., Weinberger M., Siegma-Igra Y., Lazarovitch T., Ostfeld I., Boldur I., Samra Z., Shula H., Carmeli Y., Rubinovitch B., Pitlik S. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J. Hosp. Infect. 2005, 60:256-260.
25. Peleg A.Y., Potoski B.A., Rea R., Adams J., Sethi J., Capitano B., Husain S., Kwak E.J., Bhat S.V., Paterson D.L. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother. 2007, 59:128-131.
26. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 2008, 21:538-582.
27. Pillar C.M., Draghi D.C., Dowzicky M.J., Sahm D.F. In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and etest. J. Clin. Microbiol. 2008, 46:2862-2867.
28. Reid G.E., Grim S.A., Aldeza C.A., Janda W.M., Clark N.M. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007, 27:1198-1201.
29. Roveta S., Marchese A., Debbia E.A. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy. Chemotherapy 2008, 54:43-49.
30. Sader H.S., Fey P.D., Fish D.N., Limaye A.P., Pankey G., Rahal J., Rybak M.J., Snydman D.R., Steed L.L., Waites K., Jones R.N. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006. Antimicrob. Agents Chemother. 2009, 53:4127-4132.
31. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 2007, 60:788-794.
32. Wyeth Pharmaceuticals Inc Tygacil Product Insert, Philadelphia, PA 2009, Available at, Accessed September 22, 2009. http://www.wyeth.com/hcp/tygacil.
33. Zhanel G.G., DeCorby M., Nichol K.A., Wierzbowski A., Baudry P.J., Karlowsky J.A., Lagacé-Wiens P., Walkty A., Mulvey M.R., Hoban D.J., Canadian Antimicrobial Resistance Alliance Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn. Microbiol. Infect. Dis. 2008, 62:67-80.